Neurology

Transposon Announces Final Results from a Phase 2 Study of TPN-101 for the Treatment of C9orf72-Related Amyotrophic Lateral Sclerosis and/or Frontotemporal DementiaTransposon Announces Final Results from a Phase 2 Study of TPN-101 for the Treatment of C9orf72-Related Amyotrophic Lateral Sclerosis and/or Frontotemporal Dementia

Transposon Announces Final Results from a Phase 2 Study of TPN-101 for the Treatment of C9orf72-Related Amyotrophic Lateral Sclerosis and/or Frontotemporal Dementia

TPN-101 treatment reduced the rate of decline of Vital Capacity by 50% compared to placebo after 24 weeks, an objective respiratory measure that correlates…

11 months ago
Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in CanadaCatalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in Canada

Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in Canada

CORAL GABLES, Fla., July 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company…

11 months ago
Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research SymposiumUltragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium

Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium

Presentations will include an encore of the positive interim Phase 1/2 results presented in April at the 76th Annual American…

11 months ago
Skye Bioscience Hosts Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” and Details Phase 2 Nimacimab Clinical Trial Design Including Obstructive Sleep Apnea Exploratory EndpointsSkye Bioscience Hosts Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” and Details Phase 2 Nimacimab Clinical Trial Design Including Obstructive Sleep Apnea Exploratory Endpoints

Skye Bioscience Hosts Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” and Details Phase 2 Nimacimab Clinical Trial Design Including Obstructive Sleep Apnea Exploratory Endpoints

Skye introduces collaboration with Beacon Biosignals to evaluate potential impact of Nimacimab on sleep quality and sleep apneaSAN DIEGO, July…

11 months ago
ViewMind Applauded by Frost & Sullivan for Revolutionizing Brain Health Assessment and Care with Its Ocular Digital Phenotyping SolutionViewMind Applauded by Frost & Sullivan for Revolutionizing Brain Health Assessment and Care with Its Ocular Digital Phenotyping Solution

ViewMind Applauded by Frost & Sullivan for Revolutionizing Brain Health Assessment and Care with Its Ocular Digital Phenotyping Solution

ViewMind's Ocular Digital Phenotyping solution is a holistic approach to brain and mental health that builds trust through technology, enabling…

11 months ago
Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and EpileptologistsOvid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists

Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists

Group to Advise on the Application of Ovid’s Novel Pipeline Programs to Broader Disorders of the BrainNeurologists/epileptologists Dr. Imad Najm…

11 months ago
Dyslexia Treatment Market Size to hit $11.74 billion by 2031, growing at a CAGR of 6.4%, says Coherent Market InsightsDyslexia Treatment Market Size to hit $11.74 billion by 2031, growing at a CAGR of 6.4%, says Coherent Market Insights

Dyslexia Treatment Market Size to hit $11.74 billion by 2031, growing at a CAGR of 6.4%, says Coherent Market Insights

BURLINGAME, Calif., July 22, 2024 /PRNewswire/ -- The global Dyslexia Treatment Market is projected to grow from USD 7.59 billion…

11 months ago
Digital X-ray Systems Market to be Worth $14.33 Billion by 2031 – Exclusive Report by Meticulous Research®Digital X-ray Systems Market to be Worth $14.33 Billion by 2031 – Exclusive Report by Meticulous Research®

Digital X-ray Systems Market to be Worth $14.33 Billion by 2031 – Exclusive Report by Meticulous Research®

REDDING, Calif., July 22, 2024 /PRNewswire/ -- According to a new market research report, 'Digital X-ray Systems Market Size, Share, Forecast, & Trends…

11 months ago
Bausch Health Welcomes Two New Members to the Executive Leadership TeamBausch Health Welcomes Two New Members to the Executive Leadership Team

Bausch Health Welcomes Two New Members to the Executive Leadership Team

LAVAL, QC / ACCESSWIRE / July 19, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the appointment of two…

11 months ago
AI-Based Medical Diagnostic Tools Market Set to Exceed USD 11.5 Billion by 2034: Global Surge in AI Start-up Funding Expands Diagnostic Systems Integration | TMRAI-Based Medical Diagnostic Tools Market Set to Exceed USD 11.5 Billion by 2034: Global Surge in AI Start-up Funding Expands Diagnostic Systems Integration | TMR

AI-Based Medical Diagnostic Tools Market Set to Exceed USD 11.5 Billion by 2034: Global Surge in AI Start-up Funding Expands Diagnostic Systems Integration | TMR

AI-powered diagnostic systems deliver precise and efficient diagnoses, enabling healthcare professionals to develop timely and effective treatment plans. This integration…

11 months ago